AzTrials
AzTrials

COVID-19PCOV-19NCT05855382

Prevalence of Persistent COVID-19 in Punta Arenas, Magallanes and Chilean Antarctic Region

An observational study of COVID-19, run by Universidad de Magallanes at 1 site in Chile.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This cross-sectional observational study aims to determine the prevalence of Persistent COVID-19 in 282 individuals in Punta Arenas, Magallanes and Chilean Antarctic Region. Persistent COVID-19 is a complex array of symptoms that persist or emerge for more than 4 weeks beyond SARS-CoV-2 infection. Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
COVID-19
What is being tested?
Persistent COVID-19
How many people
282 participants
Where
1 siteChile
Study dates
15 May 2023to 15 Jan 2025
How long will I take part?
13 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: To identify potential participants for this population-based study with stratified random sampling, we also considered the following eligibility criteria: (1) Diagnosed SARS-CoV-2 infection confirmed by RT-qPCR test (2) residency in Punta Arenas, (3) recruitment messages via phone calls, text messages, emails, and social media postings, and (4) referrals from collaborating healthcare providers.

Who may be able to join

  • Age ≥ 18 years
  • Individuals must be included in the COVID-19 monitoring database by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.
  • Patients able to give informed consent.

Who cannot join

  • Age < 18 years
  • Any physical, mental, immunosuppressive, or social condition that, in the investigator's judgment, might interfere with the completion of the baseline assessments and evaluations.
  • Individuals who are digitally illiterate and do not have access to nearby networks to support them during the process.

Trial locations and contacts

1 site in 1 country.

Chile1 site

  • Teaching and Research Healthcare Center of the University of Magallanes (CADI-UMAG)

    Punta Arenas, Magllanes and Chilean Antartic Region, 6200000

Other trials in Chile

About this study

Official title: A Prevalence Study of Persistent COVID-19 in Punta Arenas, Magallanes and Chilean Antarctic Region

This cross-sectional observational study aims to determine the prevalence of Persistent COVID-19 in 282 individuals in Punta Arenas, Magallanes and Chilean Antarctic Region. Persistent COVID-19 is a complex array of symptoms that persist or emerge for more than 4 weeks beyond SARS-CoV-2 infection. Recent studies suggest that up to 80% of survivors may develop chronic multi-organ dysfunction due to persistent inflammation and immune dysregulation, making it an ongoing public health concern worldwide.

The study aims to (1) describe and establish the frequency of physical and psychological signs and symptoms in adult patients who have tested positive for COVID-19, (2) identify individuals who meet the WHO case definition of Persistent COVID-19 in Chile, (3) explore risk factors associated with persistent COVID-19 to guide intervention strategies, and (4) explore inflammatory and molecular biomarkers associated with persistent COVID-19.

The research project utilizes a stratified random sampling with a mixed-methods embedded design. In the first phase, individuals diagnosed with COVID-19 will be recruited and followed up to complete the study's sample universe. A sociodemographic survey, blood sampling (including complete blood count, biochemical profile, immunoglobulin mutational status analysis, and analysis of inflammatory biomarkers), and a battery of psychological tests will be administered. In the second phase, kinesiology studies and medical consultation and evaluation will be conducted to determine if individuals have Persistent COVID-19 and to derive them to the healthcare network. In the final follow-up phase, participants diagnosed with Persistent COVID-19 will be invited to undergo musculoskeletal and respiratory assessments to complete the diagnosis of symptoms associated with the pathology.

Conditions
COVID-19
Being tested
Persistent COVID-19
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Persistent COVID-19Other

    To determine the prevalence of persistent COVID-19 diagnosis in the current study, we will identify adults between 18 and 100 years of age who have had at least one positive SARS-CoV-2 RT-qPCR test from the COVID-19 database maintained by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.

Study groups in NCT05855382
Study groupRoleWhat they receive
COVID-19Adults with at least one positive SARS-CoV-2 RT-qPCR test
Receives: Other: Persistent COVID-19

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To determine the prevalence of persistent COVID-19 in a cohort of patients in Punta Arenas

    Measured: 13 months

Secondary outcomes (23)

  1. Sociodemographic data questionnaire

    to determine the number of prior illnesses, medical treatments, and vaccination records, as well as the quality of life scales, persistent COVID-19 symptoms through self-reported survey data, and Informed Consent Comprehension Questionnaire.

    Measured: 3 months

  2. Psychological profiles

    Beck Anxiety Scale (BAI)

    Measured: 3 months

  3. Psychological profiles

    D2-R test of attention

    Measured: 3 months

  4. Psychological profiles

    Wechsler Adult Intelligence Scale (WAIS)

    Measured: 3 months

  5. Sleep quality and disorders

    Pittsburgh Sleep Quality Index (PSQI)

    Measured: 3 months

  6. Psychosocial exposures

    COVID-19 related stress questionnaire based on the Perceived Stress Scale

    Measured: 3 months

  7. Psychosocial exposures

    Normal activities and work productivity questionnaire; daily diaries

    Measured: 3 months

  8. Standard laboratory parameters

    Full blood count

    Measured: 3 months

  9. Standard laboratory parameters

    Serum chemistry test

    Measured: 3 months

  10. Inflammatory Biomarkers

    Interleukin-8 (IL-8)

    Measured: 6 months

  11. Inflammatory Biomarkers

    Interleukin-1β (IL-1β)

    Measured: 6 months

  12. Inflammatory Biomarkers

    Interleukin-6 (IL-6)

    Measured: 6 months

  13. Inflammatory Biomarkers

    Interleukin-10 (IL-10)

    Measured: 6 months

  14. Inflammatory Biomarkers

    Tumor Necrosis Factor (TNF)

    Measured: 6 months

  15. Inflammatory Biomarkers

    Interleukin-12 (IL-12p70)

    Measured: 6 months

  16. Immunological repertoire associated with persistent COVID-19

    DNA sequencing results

    Measured: 6 months

  17. Flow Cytometry Immunophenotyping

    Quantify different lymphocyte subpopulations in persistent COVID-19

    Measured: 6 months

  18. Flow Cytometry Immunophenotyping

    Quantify Age-Associated B Cells and Their Potential Role in Persistent COVID-19 Pathogenesis

    Measured: 6 months

  19. Function of the musculoskeletal system

    Fatigue Assessment Scale (FAS)

    Measured: 6 months

  20. Function of the musculoskeletal system

    Body Composition Analysis Assessment

    Measured: 6 months

  21. Function of the musculoskeletal system

    Hand Grip Strength Test

    Measured: 6 months

  22. Function of the musculoskeletal system

    Maximum inspiratory pressure test (MIP test)

    Measured: 6 months

  23. Diagnosis of prevalent COVID-19

    Clinical determination of whether the patient has persistent COVID-19 or not is necessary for referral to the appropriate healthcare system

    Measured: 8 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2023
  2. Study start15 May 2023
  3. Primary completion30 Dec 2024
  4. Study completion15 Jan 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
282 participants (actual)
Target duration
13 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT05855382
Sponsor's protocol ID
FIC-R 40036196-0
Acronym
PCOV-19
Status last verified
May 2026
First submitted
7 May 2023
Last updated
8 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The data that will be shared is all of the individual participant data collected during the trial, after deidentification.

Publications

  • Gonzalez-Puelma J, Aldridge J, Montes de Oca M, Pinto M, Uribe-Paredes R, Fernandez-Goycoolea J, Alvarez-Saravia D, Alvarez H, Encina G, Weitzel T, Munoz R, Olivera-Nappa A, Pantano S, Navarrete MA. Mutation in a SARS-CoV-2 Haplotype from Sub-Antarctic Chile Reveals New Insights into the Spike's Dynamics. Viruses. 2021 May 11;13(5):883. doi: 10.3390/v13050883.

    PubMed 34064904

  • Sarmiento Varon L, Gonzalez-Puelma J, Medina-Ortiz D, Aldridge J, Alvarez-Saravia D, Uribe-Paredes R, Navarrete MA. The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management. Front Public Health. 2023 Apr 11;11:1140353. doi: 10.3389/fpubh.2023.1140353. eCollection 2023.

    PubMed 37113165

  • Alvarado-Aravena C, Arriaza K, Castillo-Aguilar M, Flores K, Dagnino-Subiabre A, Estrada-Goic C, Nunez-Espinosa C. Effect of Confinement on Anxiety Symptoms and Sleep Quality during the COVID-19 Pandemic. Behav Sci (Basel). 2022 Oct 17;12(10):398. doi: 10.3390/bs12100398.

    PubMed 36285967

  • Sarmiento Varon L, Alvarez H, Huirimilla Casanova LC, Diaz Mora MP, Munoz Cuevas LA, Gonzalez-Puelma J, Espinoza K, Amarales L, Luhr Henriquez J, Retamal-Matus F, Uribe-Paredes R, Nunez-Espinosa CA, Estrada-Goic C, Bachelet VC, Lopez Nitsche MN, Navarrete MA. Estimating the prevalence of persistent symptoms after SARS-CoV-2 infection (post-COVID-19 syndrome): a regional cross-sectional study protocol. BMJ Open. 2025 May 30;15(5):e093844. doi: 10.1136/bmjopen-2024-093844.

    PubMed 40447416

Questions about this trial

What is this clinical trial studying?

An observational study of COVID-19, run by Universidad de Magallanes at 1 site in Chile.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine the prevalence of persistent COVID-19 in a cohort of patients in Punta Arenas (time frame: 13 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05855382, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026; AzTrials last refreshed its copy on 8 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in